Regeneron Pharmaceuticals Inc. buy Erste Group Bank AG
Start price
29.03.23
/
50%
€756.00
Target price
29.03.24
-
Performance (%)
19.37%
End price
30.03.24
€902.40
Summary
This prediction ended on 30.03.24 with a price of €902.40. The prediction had a final performance of 19.37%. Erste_Group_Bank_AG has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 1.288% | 1.288% | 39.535% | -5.284% |
| iShares Core DAX® | -1,59 % | 5,03 % | 6,33 % | 64,06 % |
| iShares Nasdaq 100 | -4,15 % | -0,13 % | 25,73 % | 86,92 % |
| iShares Nikkei 225® | -6,30 % | 0,53 % | 41,38 % | 77,87 % |
| iShares S&P 500 | -3,23 % | 0,47 % | 20,45 % | 68,19 % |
Comments by Erste_Group_Bank_AG for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at Erste Group Bank AG.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von Erste_Group_Bank_AG gewählte maximale Laufzeit wurde überschritten